Immunicom is led by healthcare industry veterans who each have over 25 years of global senior executive experience in private and Fortune 50 medical technology and pharmaceutical companies. The team is highly experienced in development, clinical and regulatory affairs, manufacturing and global commercialization related to both medical devices and pharmacologic therapies.
Immunicom's team has created over $13B in shareholder value, led 3 successful IPOs, conducted over 10 successful M&A transactions, and successfully commercialized over 50 medical products around the world.
Founder, President & CEO
Amir Jafri is the founder of Immunicom and has served as its President and Chief Executive Officer since the company’s inception in 2013. Amir has over 25 years of experience in healthcare technology and devices. As a senior executive in Fortune 50 companies and his own startups, he has managed multi-billion dollar products on a global basis and is high highly experienced with global regulatory environments. He was COO at West Health Institute, VP/CTO, VP R&D and VP Operations at Cardinal Health managing products with $1B in annual revenue (NYSE: CAH), VP/General Manager Healthcare Division at Manpower Group responsible for the healthcare practice nationwide across 35 locations (NYSE: MAN). Prior to joining Manpower, Amir founded various healthcare startups that were subsequently acquired. He has successfully managed global businesses and has a track record of success in every business he has led. Amir serves on the Board of various healthcare technology startup companies and non-profit organizations. Amir received his Bachelors of Science Degree from Houston Baptist University with a double major in Chemistry and Biology and a minor in History. He attended medical school at the University of Texas, but pursued an entrepreneurial and corporate path.
Chief Commercial Officer
Steve is a results-oriented marketing/sales, strategy and business development executive with a 30-year track record of successfully building new growth opportunities and global markets for medical technology companies of all sizes. He began his career with GE Healthcare where he worked in hospitals across the U.S., Europe and Asia developing the market for nascent technology called positron emission tomography (i.e. PET Imaging), which today is a $2.5 billion global industry. After serving in various VP level roles in Gen-Probe, Cardinal Health, and CareFusion, Steve co-founded CRISI Medical Systems which won the 2015 Frost & Sullivan "North American Award for New Product Innovation", the 2016 "Medical Design Excellence Award (MDEA)" global competition for drug-delivery devices, and was recently acquired by Becton, Dickinson and Co.
Steve received his BSEE degree from Michigan Tech University, his MSEE from Marquette University, and his MBA from Northwestern University's Kellogg Graduate School of Management. He has over a dozen issued US & international patents.
David L. Lopez, Esq., CPA
CFO and General Counsel
David Lopez has over 30 years as of experience in emerging growth situations, primarily in Life Sciences, serving as an attorney and transactional professional. He was a founding team member of Discovery Labs (Nasdaq: DSCO), was highly instrumental in taking the company public, and served as EVP, General Counsel and Chief Compliance Officer overseeing legal, regulatory, and medical affairs. He recently served as EVP, CFO and General Counsel of PrescribeWell, a Merck portfolio company. He has provided specialized consulting services to biotech and big pharma, most recently to Insmed (Nasdaq: INSM) and as Sr. Promotional Compliance/Regulatory Attorney at Otsuka. Previously, he was a Senior Attorney at a Cravath Swain spinoff, Roberts, Sheridan & Kotel, specializing in life sciences, biotechnology, medical device and high-technology. Prior to that, Mr. Lopez gained investment banking experience at Drexel Burnham Lambert and served as a consultant and auditor in “Big Four” public accounting, both in NYC.
Steve Josephs, Ph.D.
Senior Director, Research & Development
Dr. Josephs is one of the leading scientist in our space. He was at NIH and NCI for 15 years working with Dr. Robert Gallo. Dr. Josephs was also a Senior Research Scientist at Baxter Healthcare (NYSE: BAX) where he headed the virology department and molecule design. Dr. Josephs has over 100 peer reviewed articles published in area of molecular and biochemistry, virology, and ligand structure and design. He has over 10 patents to his credit and served as a Visiting Scientist at the La Jolla Institute and University of San Diego. Throughout his career, he has been involved in translational work from the bench to the clinic and in industry.
Director, Quality Assurance
Marilyn Panahi has over 25 years of lifescience industry experience in regulatory and manufacturing quality assurance. She has held various quality assurance leadership roles in both public and private lifescience companies in the San Diego area. She has extensive experience in implementation and management of GLP and GMP quality systems including: regulatory compliance; process control and process validation; change control and document control; internal and external audits; equipment calibration and validation; environmental monitoring; material management; deviation or OOS investigation; assay validation; batch release testing; product stability programs; and supporting regulatory submissions. Marilyn received her Bachelors of Science degree in Microbiology from San Diego State University. Marilyn also completed University of California San Diego Specialized Certificate in Science of Regulatory Affairs for the Drug and Biologic Industry and another for Quality Assurance/Control for the Drug and Biologic Industry. She also completed Oriel Stat A Matrix Class for Quality Systems for Medical Devices: FDA’s QSR and ISO 13485.
Board of Directors
Chairman of the Board
David has over 45 years of experience in healthcare and technology. He has been Chairman and CEO of 3 public NYSE companies and 2 private companies. He was Vice Chairman of Cardinal Health, a $90B Fortune 20 global healthcare company. David also ran the 5th largest medical technology company in the world. He has successfully completed 2 IPOs, and generated over $11B in shareholder returns over the last 10 years of his career. He has a proven track record of bringing innovative healthcare technologies to market where 8 out of the 9 companies where he was either Chairman or CEO, became multi-billion dollar businesses and the global leader in their market segment. David has served on over 20 public and private company Boards in addition to several healthcare institutional nonprofits at the national level.
Michael Perry, MBA
Board of Directors
Mr. Perry has over 30 years of leadership experience in medical technology businesses. Most recently, Mr. Perry served as CEO of privately-held CRISI Medical Systems were he led the development of its FDA-cleared medical device before completing the sale of the company to Becton Dickinson. Previously, he was CEO of CardioDynamics, a public company that he built from zero revenue to a $41 million profitable business, leading to its sale to SonoSite, Inc. for a 72% market premium. Mr. Perry was part of the senior management team at Pyxis when it was sold to Cardinal Health for $980 million. He was named Entrepreneur of the Year 2009. He has an MBA from Harvard University and a Bachelor of Mechanical Engineering degree from General Motors Institute. He serves as a Director of Immunicom and AcuSport Corporation and serves on the Advisory Board of UCSD Sulpizio Cardiovascular.
Dr. Gary Pace, Ph.D.
Board of Directors
Dr. Pace is a seasoned biopharmaceutical executive with over 30 years of experience in the industry. He has held senior positions in global product development in major biotech and medtech companies and has also co-founded a number of early stage life science companies, where he moved products from the laboratory to commercialization. He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, as well as author and co-author of over 50 research papers, reviews and patents. He served as a Director of QRxPharma Ltd (ASX: QRX) from 2001 through 2014 and is currently a Director of ResMed Inc. (NYSE: RMD), Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Transition Therapeutics Inc. (NASDAQ: TTHI). In 2003, Dr. Pace was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development. Dr. Pace holds a Ph.D. from MIT, where he was a Fulbright Scholar.